Alvotech H1 2026: Remediation Progress Partially Offsets Continued Cash Burn

What happened

Alvotech reported first-half 2026 results and a business update, showing incremental progress on AVT05 remediation but persistent negative free cash flow. The company reiterated its AVT05 resubmission timeline and highlighted early European launches of AVT03 and Mynzepli, though revenue remains concentrated in a few products. Adjusted EBITDA improved modestly but not enough to meaningfully reduce high leverage, and management acknowledged ongoing single-site manufacturing risks. No immediate covenant issues were flagged, but the balance sheet still shows negative equity and significant secured debt. The market reaction was muted, reflecting unresolved regulatory uncertainty and execution risk.

Implication

Given the minimal improvement in cash generation and the persistent single-site regulatory overhang, investors should not add exposure above $8 and should consider trimming if the stock rebounds. A more attractive entry emerges near $3.75, where the risk-reward better reflects the possibility of further FDA delays. We will reassess if H2 2026 shows positive free cash flow and a clear AVT05 approval path. Until then, the balance sheet's negative equity and high secured leverage warrant caution. Current pricing does not compensate for the concentrated execution risk.

Thesis delta

The thesis remains unchanged: Alvotech is a high-risk single-site biosimilar platform with unresolved FDA deficiencies and a strained balance sheet. H1 2026 results did not materially alter the WAIT rating, as remediation progress is offset by weak cash flow. The key catalyst for a positive re-rating is sustained positive free cash flow, which is not yet in evidence.